- Tivic Health Systems (TIVC) has undergone a significant transformation this year by licensing new assets, developing a **strong late-stage biopharmaceutical pipeline**.  **[1787740_2157666_1]** 
- The company licensed two biologic drugs, Entolimod and Entolasta, with Entolimod being a **phase three recombinant protein** for acute radiation syndrome (ARS), which has received significant funding from BARDA and the Department of Defense.  **[1787740_2157666_1]** 
- Entolimod represents a **$5.2 billion market opportunity** for ARS as a military countermeasure and stockpile drug, and also has **phase two-ready opportunities** in cancer and oncology, specifically for neutropenia, addressing a **$7.2 billion accessible market**.  **[1787740_2157666_2]** **[1787740_2157666_7]** 
- Tivic Health operates with a **capital-light model**, has a **clean cap table, no debt**, and is supported by a strong, largely confidential funding partner.  **[1787740_2157666_1]** **[1787740_2157666_7]** 
- Key milestones achieved include entering a GMP manufacturing agreement in May and completing cell line verification in September, with expectations for GMP materials and FDA meetings by the end of **2026**.  **[1787740_2157666_1]** **[1787740_2157666_7]**